GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Dividend Yield %

3D Medicines (HKSE:01244) Dividend Yield % : 0.00% (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Dividend Yield %?

As of today (2024-06-05), the Trailing Annual Dividend Yield of 3D Medicines is 0.00%.

The historical rank and industry rank for 3D Medicines's Dividend Yield % or its related term are showing as below:

HKSE:01244's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.58
* Ranked among companies with meaningful Dividend Yield % only.

3D Medicines's Dividend Payout Ratio for the six months ended in Dec. 2023 was 0.00.

As of today (2024-06-05), the Forward Dividend Yield % of 3D Medicines is 0.00%.

3D Medicines's Dividends per Share for the six months ended in Dec. 2023 was HK$0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


3D Medicines Dividend Yield % Historical Data

The historical data trend for 3D Medicines's Dividend Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Dividend Yield % Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Dividend Yield %
- - - -

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Dividend Yield % Get a 7-Day Free Trial - - - - -

Competitive Comparison of 3D Medicines's Dividend Yield %

For the Biotechnology subindustry, 3D Medicines's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines's Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Dividend Yield % falls into.



3D Medicines Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


3D Medicines  (HKSE:01244) Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


3D Medicines Dividend Yield % Related Terms

Thank you for viewing the detailed overview of 3D Medicines's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines (HKSE:01244) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines